Icatibant use in Brazilian patients with hereditary angioedema (HAE) type 1 or 2 and HAE with normal C1-INH levels: findings from the Icatibant Outcome Survey Registry Study.

Findings showed a favorable trend for more rapid effects than in patients with HAE-1/2, including a shorter median time to complete resolution and shorter median total attack duration, though the only statistically significant difference between the two patient groups in this cohort was mean time from first icatibant administration to complete resolution of symptoms.

also in 1,335 other papers